floxuridine has been researched along with Body Weight in 29 studies
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Toxicity was evaluated by determination of mortality, body weight, white blood cell (WBC) count, serum glutamic oxaloacetic transaminase (SGOT), alkaline phosphatase (ALP), total bilirubin and blood urea nitrogen (BUN), and creatinine." | 3.69 | Toxicity study of hepatic artery infusion chemotherapy with massive dose FUDR in rats. ( Sigurdson, ER; Zeng, ZS; Zhang, ZF, 1995) |
| "To shed light on the metabolic changes in glioma following therapy, uptake changes among 18F-fluoro-2'-deoxyuridine (18FUdR), 14C-thymidine (dThd), 14C-methionine (Met) and 3H-deoxyglucose (DG) in glioma model after chemotherapy were studied, as a means for interpreting clinical PET results, together with the changes in the bromodeoxyuridine (BUdR) labeling index." | 3.68 | Metabolic changes of glioma following chemotherapy: an experimental study using four PET tracers. ( Ishiwata, K; Kameyama, M; Katakura, R; Sato, K; Yoshimoto, T, 1992) |
| " The anti-tumor effective dosage of P5, P6 and their mixture, P5+P6, were obtained in dose-dependent manner." | 1.32 | Therapeutic effects of novel anti-tumor reagent, apoptosis inducing nucleosides from CD57+HLA-DRbright natural suppressor cell line on human gastric carcinoma-bearing SCID mice. ( Guo, M; Jin, A; Mori, E; Mori, T; Qi, Y; Takasaki, S, 2004) |
| " The results indicate that immunotoxic profiles of Ro 09-1390 and 5'-DFUR are very similar and characterized primarily by myelotoxicity and Ro 09-1390 is approximately two-times less toxic than 5'-DFUR on a molar basis in BDF1 mice." | 1.29 | Comparative immunotoxicity assessment of N4-Trimethoxybenzoyl-5'-deoxy-5- fluorocytidine (Ro 09-1390) and 5'-deoxy-5-fluorouridine (5'-DFUR) in BDF1 mice. ( Anderson, TD; Hayes, TJ; Horii, I; Inoue, T, 1996) |
| " 5'-DFUR was less toxic to immune organs and the functions than those by other fluorinated pyrimidines." | 1.27 | [Antitumor activity and toxicity to the immune system and intestine, of the fluorinated pyrimidines FUra, 5'-DFUR, tegafur and UFT]. ( Fujimoto, K; Ishitsuka, H; Matsuura, N; Miwa, M; Ninomiya, Y; Ryu, M, 1988) |
| " The frequency of cerebellopathy may depend on the dosage and type of administration of the drug." | 1.27 | Neurological manifestations in a phase 2 study of 13 patients treated with doxyfluridine. ( Fosså, SD; Heier, MS, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (51.72) | 18.7374 |
| 1990's | 11 (37.93) | 18.2507 |
| 2000's | 3 (10.34) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jin, A | 1 |
| Qi, Y | 1 |
| Mori, E | 1 |
| Guo, M | 1 |
| Takasaki, S | 1 |
| Mori, T | 1 |
| Rauko, P | 1 |
| Novotny, L | 1 |
| Mego, M | 1 |
| Saiko, P | 1 |
| Schott, H | 1 |
| Szekeres, T | 1 |
| Nielsen, KB | 1 |
| Tommerup, N | 1 |
| Dyggve, HV | 1 |
| Schou, C | 1 |
| Inaba, M | 1 |
| Sato, S | 1 |
| Yoshimura, M | 1 |
| Ohnishi, Y | 1 |
| Yamori, T | 1 |
| Tashiro, T | 1 |
| Zeng, ZS | 1 |
| Zhang, ZF | 1 |
| Sigurdson, ER | 1 |
| Inoue, T | 1 |
| Anderson, TD | 1 |
| Hayes, TJ | 1 |
| Horii, I | 1 |
| Hamada, A | 1 |
| Fukushima, S | 1 |
| Saneyoshi, M | 1 |
| Shimizu, S | 1 |
| Kawaguchi, T | 1 |
| Nakano, M | 1 |
| Satake, H | 1 |
| Takechi, T | 1 |
| Nakano, K | 1 |
| Saito, H | 1 |
| Uchida, J | 1 |
| Takeda, S | 1 |
| Unemi, N | 1 |
| Fukushima, M | 1 |
| Tazawa, K | 1 |
| Sakamoto, T | 1 |
| Kuroki, Y | 1 |
| Yamashita, I | 1 |
| Okamoto, M | 1 |
| Katuyama, S | 1 |
| Fujimaki, M | 1 |
| van Borssum Waalkes, M | 1 |
| Goris, H | 1 |
| Dontje, BH | 1 |
| Schwendener, RA | 1 |
| Scherphof, G | 1 |
| Nijhof, W | 1 |
| Endo, M | 1 |
| Shinbori, N | 1 |
| Fukase, Y | 1 |
| Sawada, N | 1 |
| Ishikawa, T | 1 |
| Ishitsuka, H | 3 |
| Tanaka, Y | 2 |
| Hussey, HJ | 1 |
| Todorov, PT | 1 |
| Field, WN | 1 |
| Inagaki, N | 1 |
| Tisdale, MJ | 1 |
| Toivanen, P | 1 |
| Toivanen, A | 1 |
| Ruotsalainen, P | 1 |
| Antti-Poika, I | 1 |
| Forsthoefel, PF | 1 |
| Williams, ML | 1 |
| Houghton, JA | 1 |
| Houghton, PJ | 1 |
| Wooten, RS | 1 |
| Sato, K | 1 |
| Kameyama, M | 1 |
| Ishiwata, K | 1 |
| Katakura, R | 1 |
| Yoshimoto, T | 1 |
| Takeshita, S | 1 |
| Nagatomi, H | 1 |
| Ando, K | 1 |
| Kahky, MP | 1 |
| Lind, DS | 1 |
| Cruz, AB | 1 |
| Gaskill, HV | 2 |
| Bowen, D | 1 |
| Robbins, TJ | 1 |
| White, RM | 1 |
| Rodier, PM | 1 |
| Aschner, M | 1 |
| Lewis, LS | 1 |
| Koëter, HB | 1 |
| Fujimoto, S | 1 |
| Igarashi, K | 1 |
| Shrestha, RD | 1 |
| Miyazaki, M | 1 |
| Endoh, F | 1 |
| Ohta, M | 1 |
| Togawa, Y | 1 |
| Okui, K | 1 |
| Ninomiya, Y | 1 |
| Ryu, M | 1 |
| Matsuura, N | 1 |
| Fujimoto, K | 1 |
| Miwa, M | 1 |
| Au, JL | 1 |
| Rustum, YM | 1 |
| Slocum, HK | 1 |
| Hoyle, RM | 1 |
| Banes, A | 1 |
| Bernard, S | 1 |
| Thomas, CG | 1 |
| Nishiyama, M | 1 |
| Takagami, S | 1 |
| Kirihara, Y | 1 |
| Saeki, T | 1 |
| Hirabayashi, N | 1 |
| Nosoh, Y | 1 |
| Niimoto, M | 1 |
| Hattori, T | 1 |
| Heier, MS | 1 |
| Fosså, SD | 1 |
| Williams, JP | 1 |
| Frankfurt, OS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of an All-Oral Combination of Capecitabine (X) and Cyclophosphamide (C) in Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer[NCT00589901] | Phase 2 | 60 participants (Anticipated) | Interventional | 2006-08-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
29 other studies available for floxuridine and Body Weight
| Article | Year |
|---|---|
Therapeutic effects of novel anti-tumor reagent, apoptosis inducing nucleosides from CD57+HLA-DRbright natural suppressor cell line on human gastric carcinoma-bearing SCID mice.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Body Weight; CD57 Antigens; Chromatography, Hig | 2004 |
In vitro and in vivo antileukemic effect of novel dimers consisting of 5-fluorodeoxyuridine and arabinofuranosylcytosine.
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cy | 2007 |
Macroorchidism and fragile X in mentally retarded males. Clinical, cytogenetic, and some hormonal investigations in mentally retarded males, including two with the fragile site at Xq28, fra(X)(q28).
Topics: Adult; Aged; Birth Weight; Body Height; Body Weight; Chromosome Banding; Chromosome Mapping; Electro | 1982 |
[Combination therapy of doxifluridine, pirarubicin and cisplatin for human gastric cancers implanted in nude mice].
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cisplatin; Dox | 1995 |
Toxicity study of hepatic artery infusion chemotherapy with massive dose FUDR in rats.
Topics: Alkaline Phosphatase; Animals; Antimetabolites, Antineoplastic; Aspartate Aminotransferases; Biliary | 1995 |
Comparative immunotoxicity assessment of N4-Trimethoxybenzoyl-5'-deoxy-5- fluorocytidine (Ro 09-1390) and 5'-deoxy-5-fluorouridine (5'-DFUR) in BDF1 mice.
Topics: Animals; Body Weight; Bone Marrow; Corticosterone; Deoxycytidine; Dose-Response Relationship, Drug; | 1996 |
Acyclothymidine alleviates intestinal toxicity of 5'-deoxy-5-fluorouridine without loss of antitumor activity in mice.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Body Weight; Carcinoma, Lewis Lung; Drug Syner | 1996 |
[Antimetastatic effects of UFT on murine liver metastasis model using L5178YHM lymphoma].
Topics: Animals; Body Weight; Drug Combinations; Floxuridine; Leukemia L5178; Liver Neoplasms; Male; Mice; T | 1996 |
Inhibitory effects of fluorinated pyrimidines, 5'-DFUR, UFT and T-506, in a model of hepatic metastasis of mouse colon 26 adenocarcinoma-assessment of inhibitory activity and adverse reactions at the maximum tolerated dose.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Body Weight; Colonic Neoplasms; Dose-Response Relati | 1997 |
Toxicity of liposomal 3'-5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine in mice.
Topics: Animals; Antineoplastic Agents; Body Weight; Bone Marrow; Drug Carriers; Female; Floxuridine; Ileum; | 1998 |
Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 1999 |
Effect of a fluorinated pyrimidine on cachexia and tumour growth in murine cachexia models: relationship with a proteolysis inducing factor.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Appetite Stimulants; Blood Proteins; Body | 2000 |
Transplantation of lymphoid cells into immunodeficient chickens. Dissociation in the reconstitution of B and T cell functions.
Topics: Age Factors; Animals; Animals, Newborn; Antibody Formation; Antigens; Antigens, Bacterial; B-Lymphoc | 1975 |
The effects of 5-fluorouracil and 5-fluorodeoxyuridine used alone and in combination with normal nucleic acid precursors on development of mice in lines selected for low and high expression of Strong's luxoid gene.
Topics: Abnormalities, Drug-Induced; Animals; Body Weight; Cell Survival; Drug Synergism; Female; Fetal Deat | 1975 |
Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2'-deoxyuridine.
Topics: Animals; Body Weight; Digestive System; Dose-Response Relationship, Drug; Floxuridine; Fluorouracil; | 1979 |
Metabolic changes of glioma following chemotherapy: an experimental study using four PET tracers.
Topics: Animals; Body Weight; Carbon Radioisotopes; Deoxyglucose; DNA Replication; DNA, Neoplasm; Dose-Respo | 1992 |
Alleviation of intestinal lesions by combined treatment with a 5-fluoro-2'-deoxyuridine (FUDR) derivative and alpha-difluoromethylornithine (DFMO)[correction of DMFO] in tumor-bearing mice.
Topics: Amine Oxidase (Copper-Containing); Animals; Antineoplastic Combined Chemotherapy Protocols; Body Wei | 1992 |
Prostaglandin E1 enhances tumoricidal activity of 5-fluoro-2'-deoxyuridine in rats.
Topics: Adenocarcinoma; Alprostadil; Animals; Antineoplastic Agents; Body Weight; Drug Synergism; Floxuridin | 1991 |
Interaction of 5'-deoxy-5-fluorouridine and methotrexate. A basis for reduced methotrexate toxicity.
Topics: Animals; Blood Cell Count; Body Weight; Floxuridine; Ileal Diseases; Ileum; Male; Methotrexate; Mice | 1989 |
Cell proliferation in developing brain after brief exposure to nitrous oxide or halothane.
Topics: Analysis of Variance; Animals; Body Weight; Brain; Cell Division; Female; Floxuridine; Halothane; Ma | 1986 |
Combined therapy of polyamine antimetabolites and antitumor drugs for human gastric cancer xenotransplanted into nude mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcino | 1986 |
Intraportal prostaglandin E1 ameliorates the toxicity of intraportal 2'-deoxy-5-fluorouridine in rats.
Topics: Alprostadil; Animals; Body Weight; Floxuridine; Leukocyte Count; Male; Organ Size; Rats; Rats, Inbre | 1987 |
[Antitumor activity and toxicity to the immune system and intestine, of the fluorinated pyrimidines FUra, 5'-DFUR, tegafur and UFT].
Topics: Animals; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Bone Marro | 1988 |
Biological activities of 5-fluorouracil and its prodrug 5'-deoxy-5-fluorouridine in rats.
Topics: Animals; Body Weight; Colonic Neoplasms; Drug Therapy; Female; Floxuridine; Fluorouracil; Prodrugs; | 1987 |
Effects of 2'-deoxy-5-fluorouridine on regenerating liver following partial hepatectomy in the rat.
Topics: Analysis of Variance; Animals; Body Weight; DNA; Floxuridine; Hepatectomy; Liver; Liver Regeneration | 1988 |
The antiproliferative effects of fluoropyrimidine derivatives against human tumor xenografts in a subrenal capsule assay.
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Division; Colorectal Neoplasms; Floxuridine; Fluor | 1988 |
Neurological manifestations in a phase 2 study of 13 patients treated with doxyfluridine.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Body Weight; Brain Diseases; Cerebellar Diseases; C | 1985 |
Incorporation of thymidine after administration of fluorouracil and fluorouridine to adult and embryo mice.
Topics: Abnormalities, Drug-Induced; Animals; Body Weight; Cleft Palate; Dose-Response Relationship, Drug; E | 1971 |
Enhancement of the antitumor activity of 5-fluorouracil by drug combinations.
Topics: Animals; Body Weight; Carcinoma, Ehrlich Tumor; Cell Count; Floxuridine; Fluorouracil; Hydroxyurea; | 1973 |